A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome
Public ClinicalTrials.gov record NCT05690386. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
New InsiGHTS: A Multicenter, Phase 2, Randomized, Open-label, Active-controlled, Parallel Group Clinical Trial to Investigate the Safety, Tolerability, and Efficacy of Different Dose Levels of Once-weekly Lonapegsomatropin Compared to Daily Somatropin in Prepubertal Individuals With Turner Syndrome
Study identification
- NCT ID
- NCT05690386
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Ascendis Pharma Endocrinology Division A/S
- Industry
- Enrollment
- 48 participants
Conditions and interventions
Conditions
Interventions
- Lonapegsomatropin Biological
- Somatropin Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 1 Year to 10 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 14, 2023
- Primary completion
- Oct 17, 2024
- Completion
- Nov 30, 2027
- Last update posted
- May 12, 2026
2023 – 2027
United States locations
- U.S. sites
- 19
- U.S. states
- 16
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ascendis Pharma Investigational Site | Palo Alto | California | 94304 | — |
| Ascendis Pharma Investigational Site | San Diego | California | 92123 | — |
| Ascendis Pharma Investigational Site | Aurora | Colorado | 80045 | — |
| Ascendis Pharma Investigational Site | Orlando | Florida | 32827 | — |
| Ascendis Pharma Investigational Site | St. Petersburg | Florida | 33701-4804 | — |
| Ascendis Pharma Investigational Site | Atlanta | Georgia | 30322 | — |
| Ascendis Pharma Investigational Site | Idaho Falls | Idaho | 83404 | — |
| Ascendis Pharma Investigational Site | Chicago | Illinois | 60611 | — |
| Ascendis Pharma Investigational Site | Boston | Massachusetts | 02114 | — |
| Ascendis Pharma Investigational Site | Saint Paul | Minnesota | 55102 | — |
| Ascendis Pharma Investigational Site | Las Vegas | Nevada | 89113 | — |
| Ascendis Pharma Investigational Site | Lake Success | New York | 11042 | — |
| Ascendis Pharma Investigational Site | Chapel Hill | North Carolina | 27599 | — |
| Ascendis Pharma Investigational Site | Cincinnati | Ohio | 45229 | — |
| Ascendis Pharma Investigational Site | Oklahoma City | Oklahoma | 73104 | — |
| Ascendis Pharma Investigational Site | Portland | Oregon | 97239 | — |
| Ascendis Pharma Investigational Site | El Paso | Texas | 79902 | — |
| Ascendis Pharma Investigational Site | Fort Worth | Texas | 76104 | — |
| Ascendis Pharma Investigational Site | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05690386, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 12, 2026 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05690386 live on ClinicalTrials.gov.